54.61 -0.10 (-0.18%)
After hours: 6:31PM EDT
|Bid||54.50 x 1800|
|Ask||54.69 x 1400|
|Day's Range||54.36 - 55.03|
|52 Week Range||42.40 - 66.04|
|Beta (3Y Monthly)||0.25|
|PE Ratio (TTM)||14.87|
|Earnings Date||Apr 25, 2019|
|Forward Dividend & Yield||3.20 (5.57%)|
|1y Target Est||59.07|
is expected to report quarterly earnings of 92 cents a share on sales of $4.6 billion before the market opens Apr. 25, based on a FactSet survey of 14 analysts. Altria Group is currently trading at a price-to-forward-earnings ratio of 12.8 based on the 12-month estimates of 17 analysts surveyed by FactSet. Introducing TheStreet Courses: Financial titans Jim Cramer and Robert Powell are bringing their market savvy and investing strategies to you.
FEMSA's (FMX) results for first-quarter 2019 may continue to bear impacts of soft margins and higher costs. However, the company's growth efforts may bring some relief.
The once-hot deep-value investor wasn’t able to recover from a 10-plus-year stretch during which beaten-up stocks also struggled.
What’s Expected for Altria’s First-Quarter Earnings(Continued from Prior Part)Analysts’ recommendations Of the 17 analysts covering Altria Group (MO), 47.1% recommend “buy,” 35.3% recommend “hold,” and 17.6%
What’s Expected for Altria’s First-Quarter Earnings(Continued from Prior Part)Analysts’ expectations In the first quarter, analysts project Altria Group’s (MO) adjusted EPS to fall 2.9% YoY (year-over-year) to $0.92 from $0.95, dragged down
What’s Expected for Altria’s First-Quarter Earnings(Continued from Prior Part)Analysts’ expectationsIn the first quarter, analysts expect Altria Group’s (MO) to fall 1.7% YoY (year-over-year) to $4.59 billion from $4.67 billion. During the
What’s Expected for Altria’s First-Quarter EarningsStock performanceAltria Group (MO) is set to report its first-quarter earnings on April 25. As of April 18, Altria stock was trading at $54.37, 13.7% higher than when it announced its
Colgate's (CL) growth efforts make us confident that it will likely retain the robust bottom-line surprise trend. However, soft margins and adverse currency may be deterrents.
Boston Beer's (SAM) first-quarter results are likely to reap benefits of the ongoing strength in shipments and depletions. However, soft Samuel Adams brand performance and higher costs remain woes.
“We’ve got the biggest manufacturer of cigarettes in America to hasten their own decline,” said Dan Thomson, managing director of Juul UK. , more than doubled the two-year-old company’s valuation at its previous funding round last summer.
Ah, the magic of analyst ratings! After a tough month in April, cannabis firm Hexo (NYSEAmerican:HEXO) suddenly reversed course after Bank of America analyst Christopher Carey initiated coverage. Sizing up the risk and reward profile, Carey assigned a "buy" rating on Hexo stock with a $10 price target.Source: Shutterstock The news couldn't have come at a better time. While cannabis stocks offer tremendous upside because they essentially materialize an industry that previously never existed, they're also incredibly volatile. Because this is an unprecedented sector, many investors are unsure how to approach a company like HEXO.As such, I mentioned earlier that I liked Hexo stock, even compared to relative heavyweight Aurora Cannabis (NYSE:ACB). Unfortunately, the aforementioned volatility in cannabis stocks disproportionately impacted HEXO, sending my recommendation toward a quick grave. But thanks to Carey, this bad boy gained nearly 12% on Wednesday.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks to Buy for Spring Season Growth Of course, by the time that you're reading this, this dramatic burst in Hexo stock is in the past. Do newcomers still have a chance in riding this promising, but wild bull? Underappreciated Elements Support Hexo StockThe best way I can characterize Hexo stock is as a diamond in the rough. I believe the organization has the right components in place to make a solid run. However, the credibility issues that stymie virtually all cannabis stocks will pressure HEXO. At the end of the day, it comes down to your risk tolerance.But if you're willing to take that leap, Carey argues that this weed play deserves your attention. Primarily, HEXO stock is undervalued relative to its peers. Of course, in the marijuana sector, "undervalued" is an extremely relative term. That said, many cannabis stocks have hit nosebleed levels. Therefore, HEXO at least on paper provides some assurance of future room for growth.Next, the BofA analyst mentioned that Hexo stock is levered toward a "de-risked" Canadian cannabis market. Although I wouldn't use that term specifically, I see his point. Our northern neighbors paved the way for other western and developed nations to adopt tolerant policies. While this broader dynamic is building out, management has time to hone its craft.Finally, Carey mentioned "value-add partnerships" that go beyond the scope of Hexo's existent relationship with Molson Coors Brewing (NYSE:TAP). I agree. Cannabis stocks can branch out into subsegments of the broader categories of recreational and medicinal usage. However, let's not gloss over the Molson partnership as it holds a significant key for growth.Naturally, the idea here is for Hexo and Molson to developed cannabidiol (CBD)-infused drinks. Now, CBD itself is a tailwind for the industry as it offers non-psychoactive exposure to the cannabis plant. In other words, it's a lot easier to introduce people to weed through a drink rather than a joint. Upgrade Suggests Rising Credibility for Cannabis StocksIndeed, Hexo's Molson partnership has advantages over an expected synergy like Cronos Group (NASDAQ:CRON) and Altria Group (NYSE:MO). I don't think I can ever get my parents to smoke marijuana. But to drink it in a form that won't get them stoned? That's infinitely more palatable and more socially acceptable.Invariably, that had to enter BofA's thinking process when deciding to go bullish on Hexo stock. But just the fact that the big bank is even considering cannabis stocks is a major sign. It gives the industry significant credibility, and it suggests a very viable environment in the future.While we here in the U.S. have also warmed to varying degrees of legalization, most banks won't finance cannabis-related businesses. Why? Because it comes down to that nasty roadblock called Schedule I. Despite individual state laws, cannabis falls under strict federal guidelines.Sure, we've made progress in this department, too. For instance, the 2018 farm bill won consensus at a time when bipartisanship no longer exists. And major conservative figures have more or less voiced support for full legalization.Nevertheless, that Schedule I classification remains on the books for marijuana. Unless the federal government officially extinguishes it, most banks won't touch cannabis stocks. * 5 Dividend Stocks Perfect for Retirees And while BofA isn't necessarily diving into the sector with open arms, it's essentially giving you the green light to do so. Look, Hexo stock is a risky play no matter how you cut it. But if you've got the nerve, I'd read between the lines.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for Spring Season Growth * This Is How You Beat Back a Bear Market * 7 Dental Stocks to Buy That Will Make You Smile Compare Brokers The post If You Can Tolerate Risk, Hexo Stock Is a Buy appeared first on InvestorPlace.
LOUISVILLE, Ky. (AP) — Senate Majority Leader Mitch McConnell said Thursday he plans to introduce legislation to raise the minimum age to buy tobacco products from 18 to 21 nationally, rating the health initiative as one of his top priorities.
Philip Morris Beat Analysts' ESP and Revenue Expectations in Q1(Continued from Prior Part)Stock performancePhilip Morris International (PM) outperformed analysts’ revenue and EPS expectations in the first quarter. Despite strong first-quarter
The tobacco giant was trading down, as concerns about potential legislation overshadowed better-than-expected first-quarter results.
Canopy Growth will probably purchase the rights to buy Acreage Holdings to tap the growing potential of the U.S. marijuana market. This should bolster the ETF MJ.
Speaking at an event Thursday in his home state of Kentucky, the second biggest tobacco producer after North Carolina, the Republican leader said he plans to introduce legislation in May and expects it will get bipartisan support in the Senate. McConnell said he is motivated partly by the growing popularity of vaping products among young people, which studies have shown can affect brain development and yield higher rates of addiction to other drugs.
Altria Group, Inc. -- In response to the announcement today by Senate Majority Leader McConnell for plans to introduce legislation to raise the age of pur
As the trend of marijuana legalization continues, cannabis-related stocks continue to proliferate. But fundamentals and technicals remain weak for many of the stocks in this space.
Tobacco stocks fell Thursday, after Senate Majority Leader Mitch McConnell (Repub-Ky.) said he would introduce legislation that would raise the age to buy tobacco from 18 to 21. The new age limit would apply to all vaping and tobacco products, although young members of the military would be exempted. The news comes after a long campaign by outgoing Food and Drug Administration Commissioner Scott Gottlieb to crack down on teen vaping. Altria Group Inc. shares fell 2.7%, while Philip Morris International Inc. was down 1.1%. U.S.-listed shares of British American Tobacco fell 1.3%.
Altria (MO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.